Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI)

Autor: Capdevila, J, Galofre, JC, Grande, E, Llopis, CZ, Asensio, TRYC, Gonzalez, EN, Jimenez-Fonseca, P, Sandi, JS, Saez, JMG, Eizaguirre, GR

Publikováno v: Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)

Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3046e27e9d2f21d6eceec30cd70fe174
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6612

Characterization of New Founder Alu-Mediated Rearrangements in MSH2 Gene Associated with a Lynch Syndrome Phenotype

Autor: Perez-Cabornero, L, Flores, EB, Sanz, MI, Sampedro, EV, Becares, AA, Aras, EL, Gonzalez, JC, Riu, MP, Asensio, TRYC, Munar, GC, Pino, CM, Dominguez, MD

Publikováno v: Cancer Prevention Research
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

It has been reported that large genomic deletions in the MLH1 and MSH2 genes are a frequent cause of Lynch syndrome in certain populations. Here, a cohort has been screened and two new founder rearrangements have been found in the MSH2 gene. These mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9a429d3319b4ba697d5dacc761f2ba88
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11698